Galcanezumab
| Evidence Level: L5 | Predicted Indications: 50 |
Quick Overview
| Item | Value |
|---|---|
| Drug Name | Galcanezumab |
| DrugBank ID | DB14042 |
| Brand Names (EU) | Emgality |
| Evidence Level | L5 |
| Predicted Indications | 50 |
| Top Prediction Score | 99.50% |
Approved Indication (EMA)
Emgality is indicated for the prophylaxis of migraine in adults who have at least 4 migraine days per month.
Predicted New Indications
TxGNN model predictions for potential drug repurposing:
| Rank | Indication | Score | Source |
|---|---|---|---|
| 1 | heparin cofactor 2 deficiency | 99.50% | DL |
| 2 | antithrombin deficiency type 2 | 99.41% | DL |
| 3 | factor 5 excess with spontaneous thrombosis | 99.41% | DL |
| 4 | thrombophilia | 98.99% | DL |
| 5 | migraine with brainstem aura | 98.33% | DL |
| 6 | migraine disorder | 98.07% | DL |
| 7 | atrophoderma vermiculata | 91.50% | DL |
| 8 | ulerythema ophryogenesis | 90.30% | DL |
| 9 | migraine with or without aura, susceptibility to | 89.41% | DL |
| 10 | hemorrhagic disease of newborn | 81.28% | DL |
| 11 | prekallikrein deficiency | 72.25% | DL |
| 12 | thrombotic disorder due to a platelet anomaly | 70.73% | DL |
| 13 | hypervitaminosis | 70.34% | DL |
| 14 | sciatic neuropathy | 70.24% | DL |
| 15 | obesity disorder | 68.94% | DL |
| 16 | monogenic obesity | 68.56% | DL |
| 17 | obsolete hypertelorism (disease) | 66.73% | DL |
| 18 | frontorhiny | 63.79% | DL |
| 19 | thrombophilia due to protein S deficiency, autosomal recessive | 62.92% | DL |
| 20 | thrombomodulin-related bleeding disorder | 62.82% | DL |
Showing top 20 of 50 predictions.
About TxGNN Predictions
Prediction Sources
| Source | Description |
|---|---|
| KG | Knowledge Graph - Network topology-based associations |
| DL | Deep Learning - Neural network score prediction |
Evidence Levels
| Level | Definition |
|---|---|
| L1 | Multiple Phase 3 RCTs / Systematic Reviews |
| L2 | Single RCT or multiple Phase 2 trials |
| L3 | Observational studies / Large case series |
| L4 | Preclinical / Mechanistic / Case reports |
| L5 | AI prediction only (current) |
Clinical Validation Needed
Research Use Only: These predictions are computational hypotheses that require clinical validation. They should NOT be used for clinical decision-making.
Next Steps for Validation
- Literature Review: Search PubMed for existing evidence
- Clinical Trial Search: Check ClinicalTrials.gov for ongoing studies
- Mechanistic Analysis: Evaluate biological plausibility
- Preclinical Studies: Conduct in vitro/in vivo validation
- Clinical Trials: Design and conduct human studies
Data Access
- FHIR API:
/fhir/ClinicalUseDefinition/ - CSV Download: All Predictions
- GitHub: yao-care/EuTxGNN
Citation
If using this data, please cite:
@article{huang2023txgnn,
title={A foundation model for clinician-centered drug repurposing},
author={Huang, Kexin and others},
journal={Nature Medicine},
year={2023},
doi={10.1038/s41591-023-02233-x}
}
Disclaimer: This report is for research purposes only and does not constitute medical advice. Drug repurposing predictions require rigorous clinical validation before any therapeutic application.